Psilocybin Research for OCD: A Much Earlier Stage Than Its Depression Trajectory
He read about psilocybin's Phase 3 depression trials and wants to know when the same option might reach his OCD — the honest answer is that OCD's psilocybin research sits at a genuinely much earlier, thinner stage.
C.L., a 36-year-old man, is a working artist who sells paintings through a small regional gallery and describes his studio, a converted spare room in his apartment, as "the only space where the checking mostly leaves me alone." He is otherwise healthy and lives with a longtime partner who accompanies him to visits.
His OCD, present since adolescence and centered on checking and a need for symmetry in his physical environment that has begun spilling into his painting process itself, has resisted two adequate SSRI trials and a clomipramine trial six months ago, all completed at appropriate doses and durations; his Y-BOCS today is 30. He raised psilocybin at this visit after reading about its advanced clinical trials for treatment-resistant depression, including large Phase 3 programs nearing potential approval, and asked directly why the same option isn't being offered to him.
The honest answer is that psilocybin's OCD research occupies a genuinely much earlier and thinner stage than its depression trajectory, not a parallel one running slightly behind. A single small pilot study from two decades ago showed a transient reduction in OCD symptoms after psilocybin administration in a handful of patients, and while newer, more rigorously designed trials are now underway, none have completed at the scale or with the regulatory momentum of the depression program he read about — there is no OCD equivalent of a Phase 3 trial in progress, and psilocybin remains a Schedule I controlled substance in the United States outside of narrow research and limited state-level access programs, with no approved indication for any psychiatric condition, OCD included. His genuine treatment-resistant history makes the research itself relevant to discuss honestly with him, but the practical reality is that a legitimate, currently accessible path to psilocybin for his diagnosis specifically does not yet exist outside of a formal clinical trial.
A much earlier stage of research, honestly explained
I want to correct the premise gently but directly: OCD's psilocybin evidence isn't running a few years behind depression's, it's at a fundamentally earlier stage. One small pilot study from twenty years ago, and newer trials now underway but nowhere near Phase 3 scale or regulatory momentum. It's a legitimate area of active research, and I'd tell him that honestly, but it isn't a treatment he can access today the way esketamine or even off-label ketamine might be discussed.
Agreed, and I think the honest, non-dismissive version of this conversation matters given how genuinely resistant his OCD has been across three adequate trials. I'd tell him plainly that his history would make him a reasonable candidate for a research trial if one becomes available and accessible to him, and help him understand what to actually look for — a registered OCD-specific psilocybin trial, not a general psychedelic-therapy program that may not be studying his diagnosis at all.
In the meantime, his actual next evidence-based step — augmentation of his current SSRI, which hasn't been tried yet — is still ahead of him and shouldn't get sidelined by a research conversation about an option that isn't accessible today. I'd move forward with that concretely at this visit rather than let psilocybin become the de facto plan by default just because it's the more interesting conversation to have.
Agreed: an antipsychotic augmentation trial added to his current SSRI as the concrete plan moving forward, with psilocybin research discussed honestly and specifically — including where his history would make him a reasonable future trial candidate — without becoming a substitute for the evidence-based step actually available to him today.
No disagreement among the three voices about the plan itself; the discussion's real work was making sure the more accessible, evidence-backed option didn't get quietly deprioritized in favor of the more novel one he'd come in asking about.